A Phase 3 interventional study of Atogepant 60 mg in Chronic Migraine and Episodic Migraine, sponsored by AbbVie. Completed at 24 sites in Japan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-22.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing atogepant in Migraine Disorders — 6 open to participants now, 7 under way, 4 of them phase 3. atogepant · Migraine Disorders.
Among the 21 studies testing atogepant in Migraine Disorders, this one is the 16th largest by enrollment, is the only one that started in 2020, is one of 15 in phase 3, and was the 6th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
Browse Migraine Disorders studies →6 of the 21 studies testing atogepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–70
AbbVie · Sites in United States, Canada, Denmark and 8 more countries
Ages 12–17
AbbVie · Sites in United States, Belgium, Canada and 13 more countries
Ages 6–17
AbbVie · Sites in United States, Belgium, Canada and 13 more countries
Ages 6–17
Konrad Peter Weber · Sites in Switzerland
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
atogepant: first FDA approval 2021 (QULIPTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 16 · Phase 4 4
First in 2016; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 186 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 468 across the 21 interventional studies. Of the 14 that completed or were terminated, 11 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 21 have an industry lead sponsor. The 5 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
55 studies in Migraine Disorders by AbbVie: 9 open now, 13 under way, 7 of them phase 3. Of 40 finished, 32 (80%) have results posted.
Among the 55 studies in Migraine Disorders by AbbVie, this one is the 33rd largest by enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2020, is one of 30 in phase 3, and was the 28th registered.
AbbVie’s Migraine Disorders studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing atogepant in Migraine Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 55 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the long-term safety, efficacy and tolerability of atogepant 60 mg daily for the prevention of migraine in Japanese participants with chronic (CM) or episodic migraine (EM).
The study recruited the following 2 cohorts:
3101-303-002 CM Completers: Japanese participants who completed lead-in Study 3101 303-002 (PROGRESS; NCT03855137), a Phase 3, multicenter, randomized, double-blind, placebo controlled, parallel-group study of atogepant for the prevention of CM. All 3101 303-002 CM Completers rolled over at Visit 7 (the end of the double-blind treatment period) of the lead-in study, which functioned as Visit 1 for this study, Study 3101-306-002.
De Novo EM Participants: Japanese participants with EM who were newly recruited for this study at selected sites. Participation began with a 4-week Screening/Baseline period starting at Visit -1, and those who completed the 4-week Screening/Baseline period and met all entry criteria were enrolled into the 52-week open-label treatment period at Visit 1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
3101-303-002 Completers:
De Novo EM Participants:
Exclusion Criteria:
De Novo EM Participants only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with chronic migraine (CM) who completed lead-in Study 3101-303-002 (NCT03855137) received atogepant orally as 60 mg tablets once a day (QD) for 52 weeks.
Drug: Atogepant 60 mg
Participants with episodic migraine (EM) who were newly recruited and met all study entry criteria received atogepant orally as 60 mg tablets once a day (QD) for 52 weeks.
Drug: Atogepant 60 mg
Tablets containing 60 mg atogepant
Percentage of Participants With at Least 1 Treatment-Emergent Adverse Event and Treatment-Emergent Serious Adverse Event (TEAEs/TESAEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.
Time frame: From first dose of study drug until 4 weeks following the last dose of study drug (up to 56 weeks)
Percentage of Participants With Potentially Clinically Significant (PCS) Laboratory Values (Chemistry, Hematology, Urinalysis) as Assessed by the Investigator
Clinical laboratory test values are considered PCS if they meet either the lower-limit or higher-limit PCS criteria defined in the categories below. The percentage of participants with PCS laboratory values are summarized for hematology, chemistry, and urinalysis.
Time frame: From first dose of study drug until 4 weeks following the last dose of study drug (up to 56 weeks)
Percentage of Participants With Potentially Clinically Significant (PCS) Electrocardiograms (ECGs) Findings as Assessed by the Investigator
12-lead ECGs were performed at select study visits.
Time frame: Week -4 (De Novo Participants), Day 1 (3101-303-002 Completers Only), Weeks 12, 24, 36, and 52
Percentage of Participants With Potentially Clinically Significant (PCS) Vital Sign Measurements as Assessed by the Investigator
Potentially Clinically Significant post-Baseline vital sign values are summarized for categories: systolic and diastolic blood pressures \[sitting and standing\], pulse rate \[sitting and standing\], and weight.
Time frame: From first dose of study drug until 4 weeks following the last dose of study drug (up to 56 weeks)
Percentage of Participants With Most Severe Suicidal Ideation and Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) During the Open-Label Treatment Period
The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. (Minimum total score 0, maximum total score 5; higher total scores indicate more suicidal ideation and/or suicidal behavior).
Time frame: From first dose of study drug until the last dose of study drug (up to 52 weeks)
Percentage of Participants With Most Severe Suicidal Ideation and Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) During the Safety Follow-Up Period
The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. (Minimum total score 0, maximum total score 5; higher total scores indicate more suicidal ideation and/or suicidal behavior).
Time frame: Up to 4 weeks following the last dose of study drug
| Milestone | Atogepant 60 mg Chronic Migraine | Atogepant 60 mg Episodic Migraine |
|---|---|---|
| Started | 155 | 31 |
| Completed | 130 | 28 |
| Not completed | 25 | 3 |
| Withdrew: Met withdrawal criteria at visit 1- laboratory values | 7 | 0 |
| Withdrew: Met withdrawal criteria at visit 1- ecg | 1 | 0 |
| Withdrew: Adverse event | 9 | 0 |
| Withdrew: Lack of efficacy | 4 | 0 |
| Withdrew: Withdrawal by subject | 4 | 1 |
| Withdrew: Protocol deviation | 0 | 1 |
| Withdrew: Other, not specified | 0 | 1 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.
| percentage of participants | Atogepant 60 mg Chronic Migraine | Atogepant 60 mg Episodic Migraine |
|---|---|---|
| Any TEAE | 88.4 | 90.3 |
| TESAE | 4.5 | 0.0 |
Clinical laboratory test values are considered PCS if they meet either the lower-limit or higher-limit PCS criteria defined in the categories below. The percentage of participants with PCS laboratory values are summarized for hematology, chemistry, and urinalysis.
| percentage of participants | Atogepant 60 mg Chronic Migraine | Atogepant 60 mg Episodic Migraine |
|---|---|---|
| Basophils (10^9/L): > 2.0 x Upper Limit of Normal (ULN) | 0.0 | 0.0 |
| Eosinophils (10^9/L): > 2.0 x Upper Limit of Normal (ULN) | 0.0 | 0.0 |
| Erythrocytes, Hematology (10^12/L): < 0.9 x Lower Limit of Normal (LLN) | 3.2 | 3.2 |
| Erythrocytes, Hematology (10^12/L): > 1.1 x Upper Limit of Normal (ULN) | 0.0 | 0.0 |
| Hematocrit (RATIO): < 0.9 x Lower Limit of Normal (LLN) | 0.0 | 0.0 |
| Hematocrit (RATIO): > 1.1 x Upper Limit of Normal (ULN) | 0.0 | 0.0 |
| Hemoglobin (g/L): < 0.9 x Lower Limit of Normal (LLN) | 3.3 | 0.0 |
| Hemoglobin (g/L): > 1.1 x Upper Limit of Normal (ULN) | 0.0 | 0.0 |
| Leukocytes, Hematology (10^9/L): < 0.9 x Lower Limit of Normal (LLN) | 12.8 | 17.2 |
| Leukocytes, Hematology (10^9/L): > 1.5 x Upper Limit of Normal (ULN) | 0.0 | 0.0 |
| Lymphocytes (10^9/L): < 0.7 x Lower Limit of Normal (LLN) | 1.9 | 0.0 |
| Lymphocytes (10^9/L): > 1.3 x Upper Limit of Normal (ULN) | 0.0 | 0.0 |
| Monocytes (10^9/L): < 0.5 x Lower Limit of Normal (LLN) | 0.0 | 0.0 |
| Monocytes (10^9/L): > 2.0 x Upper Limit of Normal (ULN) | 0.0 | 0.0 |
| Neutrophils (10^9/L): < 0.7 x Lower Limit of Normal (LLN) | 2.6 | 3.2 |
| Neutrophils (10^9/L): > 1.3 x Upper Limit of Normal (ULN) | 0.7 | 0.0 |
| Platelets (10^9/L): < 0.5 x Lower Limit of Normal (LLN) | 0.0 | 0.0 |
| Platelets (10^9/L): > 1.5 x Upper Limit of Normal (ULN) | 1.3 | 0.0 |
| Alanine Aminotransferase (U/L): ≥ 3.0 x Upper Limit of Normal (ULN) | 5.8 | 0.0 |
| Albumin (g/L): < 0.8 x Lower Limit of Normal (LLN) | 0.0 | 0.0 |
| Albumin (g/L): > 1.2 x Upper Limit of Normal (ULN) | 0.0 | 0.0 |
| Alkaline Phosphatase (U/L): ≥ 3.0 x Upper Limit of Normal (ULN) | 0.6 | 0.0 |
| Aspartate Aminotransferase (U/L): ≥ 3.0 x Upper Limit of Normal (ULN) | 3.2 | 0.0 |
| Bicarbonate (mmol/L): < 0.9 x Lower Limit of Normal (LLN) | 0.6 | 3.2 |
| Bicarbonate (mmol/L): > 1.1 x Upper Limit of Normal (ULN) | 0.0 | 0.0 |
| Bilirubin, Chemistry (umol/L): ≥ 1.5 x Upper Limit of Normal (ULN) | 0.6 | 0.0 |
| Calcium (mmol/L): < 0.9 x Lower Limit of Normal (LLN) | 0.0 | 0.0 |
| Calcium (mmol/L): > 1.1 x Upper Limit of Normal (ULN) | 0.0 | 0.0 |
| Chloride (mmol/L): < 0.9 x Lower Limit of Normal (LLN) | 0.0 | 0.0 |
| Chloride (mmol/L): > 1.1 x Upper Limit of Normal (ULN) | 0.0 | 0.0 |
| Cholesterol (mmol/L): > 1.6 x Upper Limit of Normal (ULN) | 0.0 | 0.0 |
| Creatine Kinase (U/L): > 2.0 x Upper Limit of Normal (ULN) | 2.6 | 0.0 |
| Creatinine (umol/L): > 1.5 x Upper Limit of Normal (ULN) | 0.0 | 0.0 |
| Glomerular Filtration Rate, Estimated (mL/min/1.73): < 60 mL/min/1.73m^2 | 1.9 | 3.3 |
| Glucose, Chemistry (mmol/L): < 0.8 x Lower Limit of Normal (LLN) | 1.9 | 0.0 |
| Glucose, Chemistry (mmol/L): > 2.0 x Upper Limit of Normal (ULN) | 0.0 | 0.0 |
| Lactate Dehydrogenase (U/L): > 3.0 x Upper Limit of Normal (ULN) | 0.6 | 0.0 |
| Phosphate (mmol/L): < 0.9 x Lower Limit of Normal (LLN) | 0.0 | 0.0 |
| Phosphate (mmol/L): > 1.1 x Upper Limit of Normal (ULN) | 0.0 | 0.0 |
| Potassium (mmol/L): < 0.9 x Lower Limit of Normal (LLN) | 0.0 | 0.0 |
| Potassium (mmol/L): > 1.1 x Upper Limit of Normal (ULN) | 0.0 | 0.0 |
| Protein, Chemistry (g/L): < 0.9 x Lower Limit of Normal (LLN) | 0.0 | 0.0 |
| Protein, Chemistry (g/L): > 1.1 x Upper Limit of Normal (ULN) | 0.0 | 0.0 |
| Sodium (mmol/L): < 0.9 x Lower Limit of Normal (LLN) | 0.0 | 0.0 |
| Sodium (mmol/L): > 1.1 x Upper Limit of Normal (ULN) | 0.0 | 0.0 |
| Urate (umol/L): > 1.2 x Upper Limit of Normal (ULN) | 0.0 | 0.0 |
| Urea Nitrogen (mmol/L): > 1.5 x Upper Limit of Normal (ULN) | 0.0 | 0.0 |
| Glucose, Urinalysis: At least 1+ | 1.3 | 0.0 |
| Protein, Urinalysis: At least 1+ | 28.7 | 26.7 |
| Specific Gravity: > 1.1 x Upper Limit of Normal (ULN) | 0.0 | 0.0 |
| pH: < 0.9 x Lower Limit of Normal (LLN) | 0.0 | 0.0 |
| pH: > 1.1 x Upper Limit of Normal (ULN) | 0.0 | 0.0 |
12-lead ECGs were performed at select study visits.
| percentage of participants | Atogepant 60 mg Chronic Migraine | Atogepant 60 mg Episodic Migraine |
|---|---|---|
| PR Interval (msec): ≥ 250 | 0.0 | 0.0 |
| QRS Duration (msec): ≥ 150 | 0.0 | 0.0 |
| QTcF Interval (msec): > 500 | 0.0 | 0.0 |
| QTcF Interval (msec): Increase from Baseline of > 60 | 0.0 | 0.0 |
Potentially Clinically Significant post-Baseline vital sign values are summarized for categories: systolic and diastolic blood pressures \[sitting and standing\], pulse rate \[sitting and standing\], and weight.
| percentage of participants | Atogepant 60 mg Chronic Migraine | Atogepant 60 mg Episodic Migraine |
|---|---|---|
| Sitting, Standing Systolic Blood Pressure (mmHg): ≥ 180 and increase from Baseline of ≥ 20 | 0.0 | 0.0 |
| Sitting, Standing Systolic Blood Pressure (mmHg): ≤ 90 and decrease from Baseline of ≥ 20 | 5.8 | 9.7 |
| Sitting, Standing Diastolic Blood Pressure (mmHg): ≥ 105 and increase from Baseline of ≥ 15 | 4.5 | 3.2 |
| Sitting, Standing Diastolic Blood Pressure (mmHg): ≤ 50 and decrease from Baseline of ≥ 15 | 0.6 | 0.0 |
| Sitting, Standing Pulse Rate (bpm): ≥ 120 and increase from Baseline of ≥ 15 | 0.6 | 0.0 |
| Sitting, Standing Pulse Rate (bpm): ≤ 50 and decrease from baseline of ≥ 15 | 1.3 | 0.0 |
| Weight (kg): Increase from Baseline of ≥ 7% | 4.5 | 3.2 |
| Weight (kg): Decrease from Baseline of ≥ 7% | 32.9 | 25.8 |
| Orthostatic Systolic Blood Pressure (mmHg): ≤ -20 | 12.4 | 6.5 |
| Orthostatic Diastolic Blood Pressure (mmHg): ≤ -15 | 3.9 | 0.0 |
| Orthostatic Pulse Rate (bpm): ≥ 25 | 4.5 | 6.5 |
The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. (Minimum total score 0, maximum total score 5; higher total scores indicate more suicidal ideation and/or suicidal behavior).
| percentage of participants | Atogepant 60 mg Chronic Migraine | Atogepant 60 mg Episodic Migraine |
|---|---|---|
| No suicidal ideation | 98.1 | 100 |
| Suicidal ideation | 1.3 | 0.0 |
| Most severe suicidal ideation: Active suicidal ideation with specific plan and intent | 0.0 | 0.0 |
| Most severe suicidal ideation: Active suicidal ideation with some intent to act, w/out specific plan | 0.0 | 0.0 |
| Most severe suicidal ideation: Active suicidal ideation w/ any method (not plan) w/out intent to act | 0.0 | 0.0 |
| Most severe suicidal ideation: Non-specific active suicidal thoughts | 0.6 | 0.0 |
| Most severe suicidal ideation: Wish to be dead | 0.6 | 0.0 |
| No suicidal behavior | 100 | 100.0 |
| Suicidal behavior | 0.0 | 0.0 |
| Most severe suicidal behavior: Actual attempt | 0.0 | 0.0 |
| Most severe suicidal behavior: Interrupted attempt | 0.0 | 0.0 |
| Most severe suicidal behavior: Aborted attempt | 0.0 | 0.0 |
| Most severe suicidal behavior: Preparatory acts or behavior | 0.0 | 0.0 |
| Completed Suicide | 0.0 | 0.0 |
| Non-suicidal self-injurious behavior | 0.0 | 0.0 |
The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. (Minimum total score 0, maximum total score 5; higher total scores indicate more suicidal ideation and/or suicidal behavior).
| percentage of participants | Atogepant 60 mg Chronic Migraine | Atogepant 60 mg Episodic Migraine |
|---|---|---|
| No suicidal ideation | 100 | 93.5 |
| Suicidal ideation | 0.0 | 0.0 |
| Most severe suicidal ideation: Active suicidal ideation with specific plan and intent | 0.0 | 0.0 |
| Most severe suicidal ideation: Active suicidal ideation with some intent to act, w/out specific plan | 0.0 | 0.0 |
| Most severe suicidal ideation: Active suicidal ideation w/ any method (not plan) w/out intent to act | 0.0 | 0.0 |
| Most severe suicidal ideation: Non-specific active suicidal thoughts | 0.0 | 0.0 |
| Most severe suicidal ideation: Wish to be dead | 0.0 | 0.0 |
| No suicidal behavior | 100 | 93.5 |
| Suicidal behavior | 0.0 | 0.0 |
| Most severe suicidal behavior: Actual attempt | 0.0 | 0.0 |
| Most severe suicidal behavior: Interrupted attempt | 0.0 | 0.0 |
| Most severe suicidal behavior: Aborted attempt | 0.0 | 0.0 |
| Most severe suicidal behavior: Preparatory acts or behavior | 0.0 | 0.0 |
| Completed Suicide | 0.0 | 0.0 |
| Non-suicidal self-injurious behavior | 0.0 | 0.0 |
Collected over All-cause mortality and adverse event tables include events reported from the time informed consent was signed to the end of the study. The median time on follow-up was 392 days for the Atogepant 60 mg Chronic Migraine group, 421 days for the Atogepant 60 mg Episodic Migraine group, and 392 days for all participants.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atogepant 60 mg Chronic Migraine | 0/155 (0%) | 7/155 (4.5%) | 108/155 (69.7%) |
| Atogepant 60 mg Episodic Migraine | 0/31 (0%) | 0/31 (0%) | 24/31 (77.4%) |
| Total | 0/186 (0%) | 7/186 (3.8%) | 132/186 (71%) |
| Event | Atogepant 60 mg Chronic Migraine | Atogepant 60 mg Episodic Migraine | Total |
|---|---|---|---|
| VERTIGOEar and labyrinth disorders | 1/155 | 0/31 | 1/186 |
| CHOLELITHIASISHepatobiliary disorders | 1/155 | 0/31 | 1/186 |
| APPENDICITISInfections and infestations | 1/155 | 0/31 | 1/186 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 1/155 | 0/31 | 1/186 |
| ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations | 1/155 | 0/31 | 1/186 |
| UTERINE LEIOMYOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/155 | 0/31 | 1/186 |
| LOSS OF CONSCIOUSNESSNervous system disorders | 1/155 | 0/31 | 1/186 |
| MIGRAINENervous system disorders | 1/155 | 0/31 | 1/186 |
| DEPRESSIONPsychiatric disorders | 1/155 | 0/31 | 1/186 |
| Event | Atogepant 60 mg Chronic Migraine | Atogepant 60 mg Episodic Migraine | Total |
|---|---|---|---|
| NASOPHARYNGITISInfections and infestations | 18/155 | 12/31 | 30/186 |
| PYREXIAGeneral disorders | 52/155 | 2/31 | 54/186 |
| COVID-19Infections and infestations | 1/155 | 6/31 | 7/186 |
| CONSTIPATIONGastrointestinal disorders | 17/155 | 4/31 | 21/186 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 10/155 | 3/31 | 13/186 |
| CYSTITISInfections and infestations | 11/155 | 1/31 | 12/186 |
| DRY EYEEye disorders | 4/155 | 2/31 | 6/186 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 6/155 | 2/31 | 8/186 |
| DIARRHOEAGastrointestinal disorders | 8/155 | 2/31 | 10/186 |
| STOMATITISGastrointestinal disorders | 3/155 | 2/31 | 5/186 |
Safety population: all participants who received at least 1 dose of study intervention (atogepant) in this extension study
| Age, Continuous(years) | Atogepant 60 mg Chronic Migraine | Atogepant 60 mg Episodic Migraine | Total |
|---|---|---|---|
| Mean | 43.4 ± 9.47 | 42.4 ± 11.95 | 43.2 ± 9.90 |
| Sex: Female, Male(Participants) | Atogepant 60 mg Chronic Migraine | Atogepant 60 mg Episodic Migraine | Total |
|---|---|---|---|
| Female | 141 | 29 | 170 |
| Male | 14 | 2 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Atogepant 60 mg Chronic Migraine | Atogepant 60 mg Episodic Migraine | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 155 | 31 | 186 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Atogepant 60 mg Chronic Migraine | Atogepant 60 mg Episodic Migraine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 155 | 31 | 186 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Jun 2020 to primary completion in Jun 2024, 47 months.
Results were first posted in Jul 2025, 1 year 1 month after primary completion.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 47 months is above that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atogepant